PharmAla Biotech Logo 800 x 422.png
PharmAla named an Intellectual Property Ontario Client
February 22, 2024 08:55 ET | PharmAla Biotech
PharmAla recieves a non-dilutive grant from IP Ontario (IPON) to support its patent work in international markets.
PharmAla Biotech Logo 800 x 422.png
PharmAla Data to be Published in ACS Chemical Neuroscience
February 20, 2024 08:55 ET | PharmAla Biotech
PharmAla's drug discovery data to be published in ACS Chemical Neuroscience; PharmAla presents data at ISRP Conference in New Orleans
MDMA Video Michael Kydd
Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video
February 12, 2024 07:00 ET | Optimi Health Corp.
Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video
MAPS-Logo-2021-Primary-Horizontal-White-Background-1200x486.jpg
MAPS Congratulates Lykos Therapeutics on Acceptance of New Drug Application for MDMA-Assisted Therapy for PTSD The FDA has accepted Lykos Therapeutics' New Drug Application, supported by two decades of research incubated by MAPS, for MDMA-assisted therapy for PTSD.
PharmAla Biotech Logo 800 x 422.png
PharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development
February 09, 2024 08:10 ET | PharmAla Biotech
PharmAla signs all-cash agreement to consult for Red Light Holland
OptimiTM-03.jpg
Optimi Announces Non-Brokered Private Placement
February 08, 2024 07:30 ET | Optimi Health Corp.
Optimi Announces Non-Brokered Private Placement
Know Your Psychedelic Drug Candidate
Optimi Health To Host MDMA Educational Quality Assurance Webinar For Clinicians And Practitioners
February 06, 2024 07:30 ET | Optimi Health Corp.
Highlights: Optimi Chief Science and Quality Assurance experts to provide in-depth access into the Company’s safety and quality standards.Optimi experts will address critical inquiries which still...
PharmAla Biotech Logo 800 x 422.png
PharmAla releases Profitable Q1 Interim Financial Statement and Business Update
January 31, 2024 10:58 ET | PharmAla Biotech
PharmAla releases Profitable Q1 Interim Financial Statement, and will host investor webinar to discuss prominent changes to the business & FDA timelines
huxley-vertical.png
Huxley Health Inc. Provides Corporate Update - Appoints Bruce Linton as Chairman
January 30, 2024 08:30 ET | Huxley Health Inc
Huxley Health Inc. provides corporate update including groundbreaking IP filings and appointment of Mr. Bruce Linton as Chairman.
PharmAla Biotech Logo 800 x 422.png
PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada
January 25, 2024 12:09 ET | PharmAla Biotech
PharmAla granted a Health Canada Controlled Drugs and Substances Dealer's License